Asieris Appointed Dr. Susan Wang as Senior Vice President of Global Business Development

Shanghai, China, July 1, 2020 – Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced the appointment of Dr. Susan Wang as Senior Vice President of Global Business Development. Susan will report directly to CEO Dr. Kevin Pan, and will be leading commercial and business development functions of Asieris and driving establishment of global strategic partnerships, commercialization strategy in China, M&A of new drug projects, and maintenance of existing collaborations.

Dr. Susan Wang has nearly 25 years of professional experience and successful deliveries in the fields of new drug R&D, commercialization, corporate development, and strategic planning. Before joining Asieris, she served as VP of Commercial Development at BTG International, now part of Boston Scientific, responsible for commercialization, business and strategic development in the Asia Pacific region including Greater China. During her tenure at BTG, Susan led the establishment of APAC regional offices and managed sales & marketing teams, and rapidly launched new products to the market. She was also involved in the global portfolio strategy and led equity investment and strategic collaboration with Chinese partners.

Susan also has extensive experience in new drug research and development. She worked as a scientist at ICOS Corporation and contributed to the development of Cialis® for treatment of erectile disfunction. After facilitating the formation of Lilly/ICOS JV, she led the clinical pharmacology function to the approval of Cialis® by FDA. She was also the co-founder of Endocyte (later acquired by Novartis). Susan Wang graduated from Chemistry Department of Fudan University, and received her Ph.D. in Biochemistry from Purdue University, USA.

“Susan’s success in strategic planning and business development of the pharmaceutical industry, her extensive experience from new drug R&D to commercialization, as well as her in-depth understanding of the Asia Pacific market, especially the China market, are a great asset to Asieris,” commented Kevin Pan, CEO of Asieris. He went on to say, “Asieris has initiated its commercialization plan for the China market. We will build marketing and sales team, and cooperate with international companies on the development of our products in overseas market. I believe Susan will make a significant contribution to to the rapid growth of Asieris.”